Transdermal [ftcn]
Estradiol [horm, phsu, strd]
F- [inch, phsu]
Alpha [inpr]
Isoprostane [bacs, eico]
Levels [qlco]
postmenopausal [tmco]
Women [popg]
Objective [inpr]
F- [inch, phsu]
Alpha [inpr]
Isoprostanes [bacs, eico]
considered [idcn]
Reliability [qnco]
Index [inpr]
In Vivo [spco]
Oxidative Stress [comd]
GIVEN [cnce]
Oxidative Stress [comd]
pathogenesis [ftcn]
Atherosclerosis [dsyn]
investigated [ftcn]
effects [qlco]
Hormone Therapy [topp]
Plasma [bdsu]
F- [inch, phsu]
Alpha [inpr]
Isoprostanes [bacs, eico]
Design [acty]
Health [idcn]
postmenopausal [tmco]
Women [popg]
treated [topp]
randomized [resa]
Trial [resa]
Estradiol [horm, phsu, strd]
Orally [spco]
mg day [qnco]
Women [popg]
MU/day [qnco]
Women [popg]
4 Weeks [tmco]
Then [tmco]
Women [popg]
Group [idcn]
Assigned [ftcn]
Oral [spco]
Progestagen [horm, phsu, strd]
progesterone, micronized [horm, phsu, strd]
mg day [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
mg day [qnco]
2 Weeks [tmco]
Additional [ftcn]
Plasma sample [bdsu]
Collected [idcn]
End [spco]
treatment [ftcn]
Estradiol [horm, phsu, strd]
Alone [qnco]
Estradiol [horm, phsu, strd]
Plus [qlco]
Progestagen [horm, phsu, strd]
F- [inch, phsu]
Alpha [inpr]
Isoprostanes [bacs, eico]
Measured [qlco]
commercial [inpr]
Enzyme Immunoassay [lbpr]
reduction [npop]
Levels [qlco]
F- [inch, phsu]
Alpha [inpr]
Isoprostanes [bacs, eico]
Detected [fndg]
Women [popg]
Receive [qlco]
Transdermal [ftcn]
Estradiol [horm, phsu, strd]
Alone [qnco]
Combination [qlco]
medroxyprogesterone acetate [horm, phsu, strd]
Conclusions [idcn]
Transdermal [ftcn]
Estradiol [horm, phsu, strd]
Alone [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
Decreased [qnco]
Plasma [bdsu]
F- [inch, phsu]
Alpha [inpr]
Isoprostanes [bacs, eico]
Additional [ftcn]
Details [qlco]
Estradiol [horm, phsu, strd]
Oxidative Stress [comd]
Relevant [qlco]
Mechanism [ftcn]
Atherogenesis [patf]
